Historical record - last NADAC effective date: 1/5/2018
Product Information
INVANZ 1 GM VIAL is a brand product labeled by Merck Sharp & Dohme LLC, priced at $122.4195 per EA under NDC 00006384371. Its NADAC has been published 269 times since Nov 28, 2013.
FDA first approved this application on Nov 21, 2001. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the ertapenem sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 g/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006384371
Classification
Brand
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
1/5/2018
Active Ingredients
ERTAPENEM SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021337FDA Approved
11/21/2001
TE Code
AP
On Market Since
11/21/2001
Pharmacological Classes
Price Statistics
The NADAC for INVANZ 1 GM VIAL has been published 269 times since Nov 28, 2013, and over the history we have for it it has risen 85.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $122.4195 per EA |
|---|---|
| All-time high | $122.4195 (Jan 16, 2019) |
| All-time low | $65.9979 (Nov 28, 2013) |
| Median price | $89.3621 |
| Average price | $93.4798 |
| Largest weekly change | +9.9% (Jan 17, 2018) |
| Weeks tracked | 269 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+85.5%
Last surveyed Jan 16, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 77% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of INVANZ 1 GM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for INVANZ 1 GM VIAL, manufactured by Merck Sharp & Dohme LLC, is $122.4195 per EA (NDC 00006384371), effective Jan 16, 2019.
How has the price of INVANZ 1 GM VIAL changed over time?
Over the history we have for it, the NADAC for INVANZ 1 GM VIAL has risen 85.5%. It has been tracked across 269 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for INVANZ 1 GM VIAL?
Since Nov 28, 2013, the NADAC for INVANZ 1 GM VIAL has ranged from a low of $65.9979 (Nov 28, 2013) to a high of $122.4195 (Jan 16, 2019), with a median of $89.3621 per EA.
Are there cheaper alternatives to INVANZ 1 GM VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERTAPENEM 1 GRAM VIAL, is $27.7551 per EA — about 77% below INVANZ 1 GM VIAL.
Who manufactures INVANZ 1 GM VIAL?
INVANZ 1 GM VIAL (NDC 00006384371) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.